Adalimumab-induced cervical lymph node tuberculosis
10.3760/cma.j.cn114015-20240103-00002
- VernacularTitle:阿达木单抗诱发颈部淋巴结结核
- Author:
Guiying WU
1
;
Guilan MU
;
Hongbin LI
;
Yong WANG
;
Lijie BAI
Author Information
1. 内蒙古医科大学附属医院风湿免疫科，呼和浩特 010050
- Publication Type:Journal Article
- Keywords:
Tuberculosis, lymph node;
Tumor necrosis factor inhibitors;
Adalimumab
- From:
Adverse Drug Reactions Journal
2025;27(3):188-189
- CountryChina
- Language:Chinese
-
Abstract:
A 38-year-old male patient with ankylosing spondylitis received subcutaneous injection of adalimumab 40 mg once every 2 weeks. After 21 months of medication, the patient developed fever, fatigue, swelling, and pain in the right neck lymph node and throat. Laboratory tests showed that the tuberculin test was strong positive, mycobacterium tuberculosis γ-interferon release test was 1 911.98 ng/L, and erythrocyte sedimentation rate was 27 mm/1 h. The biopsy of right neck lymph node showed granulomatous inflammation of the lymph node. The patient was diagnosed with cervical lymph node tuberculosis, which was considered to be related to adalimumab. The drug was stopped and anti-tuberculosis treatments were given. The next day, the patient′s temperature returned to normal. After 5 days, the swelling and pain of cervical lymph nodes and throat, and the fatigue were relieved gradually. After 45 days, the above symptoms in the patient disappeared.
